Abstract
AbstractSixteen ferulic amide (FA) derivatives were designed, synthesized and evaluated as multi‐target inhibitors against Alzheimer's disease (AD). In vitro studies indicated that most of the compounds showed significant potency to inhibit acetylcholinesterase (AChE) and self‐induced β‐amyloid (Aβ) aggregation. Specifically, a dimeric FA analogue with a diamide linker (compound 4 c) exhibited the potent ability to inhibit AChE (IC50, 0.35 μM) and the good Aβ aggregation inhibition (46.6 % at 20 μM). The structure‐activity relationships were also discussed as well as their binding conformation and simultaneous interactions mode were further clarified by the molecular docking studies. Moreover, it also produced good effects against scopolamine‐induced cognitive impairment in vivo. These results suggested that compound 4 c was a promising drug candidate against AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
